Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-613P is a non-coding processed pseudogene belonging to the U6 small nuclear RNA family. Unlike its parent gene (U6 snRNA, which is involved in the spliceosome and mRNA splicing[3][5][7]), RNU6-613P does not encode a functional snRNA due to accumulated mutations and structural changes. Pseudogenes like RNU6-613P result from retrotranspositional events (often involving LINE elements) that duplicate snRNA sequences into new genomic locations where they typically lose their original function[5]. RNU6-613P is catalogued in genome databases (e.g., NCBI, Ensembl) as a human pseudogene on chromosome 2[4][8]. Processed snRNA pseudogenes are common in mammalian genomes but do not participate in canonical biological processes, have no therapeutic relevance, and are usually not associated with clinical disease or drug action[5][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 613, pseudogene (RNU6-613P).